| HIGHLIGHTS FROM IDSA
97 Oral Ganciclovir
Maintenance: The Argentine Study
A study presented at the IDSA meeting by the Argentine Oral
Ganciclovir Study Group showed promising data in individuals with CMV disease who were
also taking a protease inhibitor-containing antiretroviral regimen. In this open-label,
non-comparative, multicenter prospective study, 41 patients were enrolled to assess the
safety and effectiveness of oral ganciclovir following intravenous induction with either
ganciclovir or foscarnet. Effectiveness was assessed by ophthalmoscopy to measure the
progression of the edge of a retinal lesion or the appearance of new lesions, or
extraocular disease. In those patients taking PI, the mean time to disease progression was
157 days compared to a mean of 76 days in those without the PI.
These data confirm the safety and efficacy of oral
ganciclovir following IV induction and show that the use of PI-containing regimens seems
to extend the window of time before the progression of CMV disease.
Table of Contents |
